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Background: Conventional cardiac pacemakers are still often regarded as a contraindication to magnetic resonance
imaging (MRI). We conducted this study to support the hypothesis that it is safe to scan patients with cardiac pacemakers
in a 1.5 Tesla MRI, if close supervision and monitoring as well as adequate pre- and postscan programming is provided.
Methods: We followed up 356 patients (age 61.3 ± 9.1 yrs., 229 men) with single (n = 132) or dual chamber (n = 224)
cardiac pacemakers and urgent indication for a cranial MRI for 12 months. The scans were performed at 1.5T. During
the scan patients were monitored with a 3-lead ECG and pulse oximetry. Prior to the scan pacemakers were
programmed according to our own protocol.
Results: All 356 scans were completed without complications. No arrhythmias were induced, programmed parameters
remained unchanged. No pacemaker dysfunction was identified. Follow-up examinations were performed immediately,
2 weeks, 2, 6, and 12 months after the scan. There was no significant change of pacing capture threshold (ventricular
0.9 ± 0.4 V@0.4 ms, atrial 0.9 ± 0.3 V@0.4 ms) immediately (ventricular 1.0 ± 0.3 V@0.4 ms, atrial 0.9 ± 0.4 V@0.4 ms) or at
12 months follow-up examinations (ventricular 0.9 ± 0.2 V@0.4 ms, atrial 0.9 ± 0.3 V@0.4 ms). There was no significant
change in sensing threshold (8.0 ± 4.0 mV vs. 8.1 ± 4.2 mV ventricular lead, 2.0 ± 0.9 mV vs. 2.1 ± 1.0 mV atrial lead) or
lead impedance (ventricular 584 ± 179Ω vs. 578 ± 188Ω, atrial 534 ± 176Ω vs. 532 ± 169Ω) after 12 months.
Conclusions: This supports the evidence that patients with conventional pacemakers can safely undergo cranial MRI in
a 1.5T system with suitable preparation, supervision and precautions. Long term follow-up did not reveal significant
changes in pacing capture nor sensing threshold.
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It is estimated that 50% to 75% of patients with implantable
cardiac devices will need magnetic resonance imaging
(MRI) at some point after implantation [1]. Despite newly
developed MRI-safe devices and leads [2,3], the majority of
cardiac pacemaker patients will still present with conven-
tional cardiac pacing devices for the next decade. Thus, the
presence of a permanent pacemaker is still often considered
a contraindication to MRI [4], and device manufacturers
warn against MRI procedures for patients with such devices* Correspondence: DrMuehling@aol.com
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unless otherwise stated.[5-7]. There have been at least 17 supposed MRI-associated
deaths worldwide among patients with pacemakers, but
none of the deaths occurred during appropriate physician-
supervised monitoring [8]. Thus redundant monitoring,
relevant pre-MRI reprogramming, and specific absorption
rate (SAR) management, are the cornerstones of the risk
mitigation strategies when scanning device patients [9]. Re-
cently, a position paper on this topic was published stating
that on a case-by-case basis, the diagnostic benefit from
MRI may outweigh the risks for some pacemaker and ICD
patients [10]. Articles have been published demonstrating
the relative safety of scanning patients with pacemakers
[11,12]. In a larger group of patients (>400) it has been
shown, that with appropriate precautions, MRI can be doneral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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device variables and programming may occur, electrophysi-
ologic monitoring during MRI is essential. Thus, follow up
studies were limited in the number of patients (n = 55) and
time of follow-up after their scan (up to 99 days). We con-
ducted this study on a large number of patients (>300) with
a variety of pacemakers undergoing an urgent cranial MRI.
Several follow-up exams were analyzed up to 12 months
after scanning to support the hypothesis that it is safe to
scan patients with cardiac pacemakers at 1.5 T, if close
supervision and monitoring as well as adequate pre- and
postscan programming is provided.Methods
Eligible subjects consisted of patients with implanted per-
manent pacemakers and an indication for an urgent cranial
MRI indicated by their referring neurologist or neurosur-
geon and no acceptable imaging alternative (due to super-
iority of MRI or contraindication to the alternative imaging
modality). Devices must have been implanted at least
2 months prior to the MRI scan and have a battery status
of “Beginning of life” (BOL). Patients who had an epicardial
pacing lead or a known or suspected lead fracture were ex-
cluded. Study subjects were enrolled between July, 2004
and January 2012. The study complied with the Declaration
of Helsinki and was approved by the local Institutional
Review Board (Ludwig-Maximilians-University Munich,
Medical Faculty).
Study protocol
Prior to the scan, all participants received education re-
garding potential risks (irreversible device damage or mal-
function, thermal injury, arrhythmias) and had to give
written, informed consent to participate in the MRI scan.
Underlying rhythm was confirmed (Figure 1). Full inter-
rogation of all device information and impedance, sensing
and capture function are measured immediately before
and after MRI and at every follow-up exam (Figure 2).
Sensing and impedance were measured using the auto-
mated features of the manufacturer’s program. After the
scan, and at every follow up patients were asked for clinical
symptoms. Troponin I serum levels were also obtained
within 6-12 hrs. after the scan. Follow-up interrogations
were performed at 2 weeks, 2, 6, and 12 months after the
scan together with a screening of the pacemaker and leads
for loss of capture, unexpected generator malfunction or
failure, device resetting, or early battery depletion.
During the scan all pacemakers were programmed to
an asynchronous stimulation mode (VOO or DOO) if the
patient was pacemaker dependent, or to a subthreshold
pacing without changes to the sensing parameters in non
pacemaker dependent patients. If possible, magnet re-
sponse, rate response, premature ventricular contractionresponse, noise response, ventricular sense response, con-
ducted atrial fibrillation response, and tachyarrhythmia
functions (monitoring, antitachycardia pacing) were dis-
abled. Histograms and event logs were saved prior to scan.
After the MRI scan was completed, each device was repro-
grammed to its pre-scan settings. If patient tolerated, pulse
amplitude and pulse duration were doubled immediately
after the MRI exam according to our own security protocol
to avoid ineffective stimulation due to an increase of pacing
capture threshold. Pacing capture thresholds were restored
to initial values at the 8-weeks-interrogation period.
All MRI scans were performed on a Siemens Symphony
1.5 T scanner. Scans were performed using usual protocols
with peak SAR limited to 2 W/ kg bodyweight. Scan time
was limited to 30 minutes. Turbo spin echo, FLAIR, and
diffusion sequences were permitted. Continuous monitor-
ing was performed with an in-vivo, non-invasive monitor-
ing system including telemetry and continuous pulse
oximetry with plethysmographic waveform. Blood pressure
measurements were obtained every 3 minutes. A cardiolo-
gist was present for the entire scan and resuscitation equip-
ment was available in the MRI suite. Staff was trained
according to our in-house protocol reported earlier [14].
Statistics
Statistical analysis was performed using SigmaStat for
Windows (V 3.10; Systat Software GmbH; Erkrath;
Germany). The Shapiro–Wilk test was used to assess
normality. Analysis was performed using the paired
Wilcoxon rank sum test with continuity correction for
continuous variables, and the Kruskal–Wallis test for
categorical data. Comparison between pre- and follow-
up-scans was performed using ANOVA. A two-sided P-
value of <0.05 was considered significant.
Results
We examined 356 patients (64,3% male), mean age 61,3 ±
9,1 years with indication for an urgent cranial MRI. Indi-
cations were known or suspected cerebral tumor in 74,8%,
s.p. glioblastoma resection in 16,5%, and vasculitis in 8,7%.
Indications for pacemaker implant were sick sinus syn-
drome in 33,0%, bradicardic atrial fibrillation in 27,9%,
symptomatic AV Block II° in 19,1% or III° in 20,0%. Mean
time after pacemaker implantation or lead implantation at
MRI examination was 40 months ± 28 months (range 2 -
97 months). Intrinsic patient rhythm assessed prior to the
MRI is displayed in Figure 1. 241 patients were pacemaker-
dependent. Mode and lead information are shown in
Table 1. Pacemaker and lead manufactures are shown in
Tables 2 and 3. Follow up was completed in 348 after
2 months, 346 after 6 months and 338 patients after
12 months.
All 356 scans were completed without immediate com-
plications. No clinical symptoms consistent with device
Figure 1 Underlying rhythm prior to MRI.
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curred during MRI examinations. No hemodynamic rele-
vance of asynchronous stimulation was monitored. No
procedures were terminated due to clinical events or pa-
tient complaints. Diagnostic questions were answered in
all sequences, despite the unavoidable artifacts due the
pacemaker or leads.
All devices were functioning appropriately after MRI. Al-
though in 37 devices (10,4%) Power- on-Reset occured and
in some reprogramming was necessary: Medtronic (Thera
n = 6, Sigma n = 4), Pacesetter (n = 6), Pulsar (n = 2) partial
or full reset occurred but battery voltage remained stable
and battery impedance remained unchanged or slightly in-
creased (no reprogramming necessary); St.Jude integrity/
verity (n = 9), Vitatron T-series (n = 10) ERI was triggered
and the ERI message could be cleared with the programmer
to normal function after the scan.Figure 2 Time schedule and follow-up plan.In 310 of 356 patients no change in pacing threshold was
observed. In 27 patients a maximum increase of 0.2 V and
in 19 patients a maximum increase of 0.4 V was observed.
The maximum relative increase in these patients was 40%.
Thus also in these patients the increase was below the rec-
ommended safety margin of a double threshold (or 200%)
for pacing capture or sensing. consequently, there was no
need to permanently increase output or sensing threshold
after MR procedure other than we recommended in our
protocol for safety reasons.
No immediate or late pacemaker dysfunction was regis-
tered. There was no increase in Troponin I level within
12 hours after the MRI. Programmed parameters remained
unchanged. Data for pacing capture, sensing threshold and
lead impedance at 2 weeks, 2, 6, and 12 months after the
scan are displayed in Figures 3, 4 and 5. At no time a sig-
nificant increase in pacing capture threshold or sensing
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ance was not registered. Increased pulse duration and pulse
amplitude could be restored to initial programming in all
patients at the 8-weeks-interrogation.
Discussion
Although it has been shown that MRI can be safely per-
formed in patients with selected conventional implantable
cardiac devices without serious adverse events [12], MRI
is currently unavailable for a large proportion of patients
with permanent pacemaker. A recent risk assessment of
pacemaker patients who undergo MRI in a 1.5 T scanner
in comparison to a control group of pacemaker patients
who did not undergo MRI showed no deaths, device fail-
ures requiring generator or lead replacement nor arrhyth-
mias. Observed were minimal decreases in battery voltage.
Although, statistically significant differences between the
MRI and control groups for the change in pacing lead im-
pedance and pacing threshold were seen, these differences
were not clinically relevant [15].
The results of the present study show that cranial MRI
can be performed safely using a protocol that incorpo-
rates device programming to minimize inappropriate ac-
tivation or inhibition of bradyarrhythmia therapies, and
limitation of the estimated whole-body averaged SAR of
MRI sequences without additional device selection. This
is in agreement with a recent smaller study [16]. As anTable 2 Pacemaker models
Pacemaker n
ELA Chorus 6








St. Jude integrity 6
Vitatron (Selection, 9000, Adapta, T70DR) 101additional security measure, we temporarily increased
pacing capture parameters for a period of 2 months after
the scan. To the best of our knowledge, our current study
shows the largest source of data and the longest follow up
(12 months) in an unselected patient (n = 356) and device
population undergoing cranial MRI in a 1.5 Tesla scanner.
Patients remained asymptomatic during the scan. Further-
more, no clinical relevant changes in pacing and sensing
parameters was recorded. Our protocol excludes device
leads that are prone to heating owing to lack of cooling by
blood flow. Neither clinical heating nor significant change
in pacing threshold (>1 V) as an indirect sign of thermal
injury of the electrode–tissue boundary was identified.
Newer devices contain only a limited amount of ferromag-
netic material. As a result, the force and torque are limited,
varying between 0.05 and 3.6 Newton for pacemakers. For
reference, forces <2 N will not be felt by patients [17]. Lead
tips are never moved magnetically as they do not possess
ferromagnetic materials [18,19].
We and others plead for limiting SAR as an additional
safety measure [20]. The current scientific statement from
European Society of Cardiology recommends a SAR limit
of 2 W/kg [10]. However, earlier data using SAR of up to
2 W/kg showed significant pacing threshold changes oc-
curred in 9.4% of patients [11]. In a series with a 1.5 T
scanner with peak SAR limited to 1.5 W/kg significant in-
creases in pacing thresholds were seen in only 3.1% of
leads [21] and no significant adverse events were seen in
another study when peak SAR was kept to <2.0 W/kg
[12]. We purposely used a SAR limited to 2 W/kg body-
weight for safety reasons, and we did not observe a signifi-
cant change of pacing threshold. Irrespective of peak SAR
level, preparations must be in place to address potential
device failure during or following a scan.
Pacing threshold changes have been attributed to heating
at the lead-tissue interface. In vitro models have detected
local tissue heating up to 23.5°C during exposure of a
pacing system to the MRI environment [22]. Temperature
changes were found to a maximum of 45.9°C at the lead tip
with a 1.5-T scan [23]. Animal studies evaluated local tissue
heating with a peak SAR set to 3.8 W/kg [24] and found no
Figure 3 Pacing capture threshold for atrial and ventricular leads prior and post MRI and during 2 weeks (n = 356), 2 (n = 354),
6 (n = 346), and 12 months follow-up (n = 338).
Figure 4 Sensing threshold for atrial and ventricular leads prior and post MRI and during 2 weeks (n = 356), 2 (n = 354), 6 (n = 346),
and 12 months follow-up (n = 338).
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Figure 5 Impedance for atrial and ventricular leads prior and post MRI and during 2 weeks (n = 356), 2 (n = 354), 6 (n = 346), and
12 months follow-up (n = 338).
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MRI of the head and lumbar regions at 1.5 T had
temperature changes ≤ 0.5°C [25], it has been recognized
that the lead lengths (the longer, the higher) and position
(more in the right than in the left hemithorax) will affect
temperature changes with the highest temperatures being
at the tip of the ventricular electrode [26,27]. Furthermore,
it has been demonstrated that abandoned leads exhibit
greater lead tip heating compared to pacemaker attached
leads [28].
In the present study, no significant immediate or long-
term changes in device or lead parameters were observed.
The lack of any significant changes in device parameters
in the present study may be related to avoidance of non-
transvenous epicardial leads, limitation of estimated SAR,
or improved electromagnetic interference protection in
more modern devices.
There have been reported changes in reed switch activity
during an MRI examination [12,29]. Reed switch operation
can result in asynchronous pacing [30], with an increased
likelihood of induction of arrhythmias. Reed switch action
are unpredictable, depending on the strength of the mag-
netic fields [19]. In our study approximately 15% of patients
had reed switch activation with asynchronus stimulation in
patients with spontaneous heart rate of > 60/min. No clinic-
ally relevant events occurred during scanning.
The use of asynchronous pacing in non-pacemaker-
dependent patients during the scan has been criticized[31,32] due to induction of ventricular arrhythmias. 0V0,
0D0, 000, or subthreshold programming were proposed as
an alternative. We and others [33] believe that induction
of tachyarrhythmias during asynchronous pacing is ex-
tremely rare and our strategy followed current general rec-
ommendations [10]. Concerns about the potential for
induction of ventricular fibrillation during asynchronous
pacing in patients with a spontaneous rhythm, have made
the use of continuous ECG telemetry and the availability
of resuscitation personnel and equipment imperative [34].
There is controversy about reprogramming the pacemaker
before the MRI examination [35,36]. Although the American
Heart Association and American College of Radiology do
not consider it necessary to reprogram the pacemaker,
many studies regarding MRI protocol among patients with
pacemakers require pacemakers to be placed in an asyn-
chronous mode before imaging.
Limitations
The current study cannot be extrapolated to 3 T MRI scan-
ners. Furthermore, it cannot be used to risk stratify recently
implanted systems or to generators at ERI or EOL. As no
CRT or ICD devices were included, conclusions regarding
this subgroup of devices cannot be drawn from our study.
According to our and others findings, the data on MRI
are heterogeneous, and a definitive statement cannot be
made about imaging patients with pacemakers. In particu-
lar in patients with older devices, unpredictable changes in
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for close monitoring during, and careful device interroga-
tion after scanning.
The MRI environment is dynamic. Multiple interre-
lated factors may influence the risk in the MRI scanner.
This includes not only SAR level and body landmark,
but also MRI manufacturer, generator and lead system
manufacturer and model [17]. The proximity of the gen-
erator to the end of the bore, proximity of the generator
to the surface of the bore, body habitus, lead geometry
and loops as well as lead system integrity [38,39] may
also play a role. There may be an unpredictable change
in pacemaker function such as inhibition, rapid ven-
tricular pacing occur [30] or no change at all [40]. Further-
more there can be switching to demand mode, ventricular
backup pacing activation, and electrical reset [41]. Al-
though lead and implant geometry may play a role in lead
heating [26], these variables were not included in the ob-
servation of the study.
Conclusion
MRI of patients with pacemakers may be considered
with caution, and with the benefits outweighing the risks
of the examination. The presence of a permanent pace-
maker no longer represents a strict contra-indication to
MR in carefully selected clinical circumstances provided
that specific strategies are followed. Regarding lead heating
concerns and possible scar formation around the lead tip,
we consider that a last pacemaker check-up 2 months
after the scan should be sufficient. Until then, any scar for-
mation would be completed and any increased in pacing
threshold should have occurred. We speculate if the pa-
tient is appropriately monitored and SAR limits are
respected, that scan times over 30 minutes will not result
in significant other changes to the device parameters than
we observed.
To date, no known deaths have been reported of patients
with pacemakers or implantable cardioverter-defibrillators
(ICD) undergoing MRI under the supervision of a physician
while on telemetry.
Although, given the infinite possibilities of electromag-
netic interferences and data published previously, the ab-
solute safety of pacemakers and ICD and MRI interactions
cannot be assured. While the results are encouraging, one
should not assume that MRI may be performed without
limitations.
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